Major Research Findings

Two studies have shown that avatrombopag is effective in treating blood disorders caused by chemotherapy and radiation therapy. 2 demonstrated that avatrombopag increased platelet counts and reduced the need for transfusions in patients with severe and refractory chemotherapy-induced thrombocytopenia (CIT) who had failed multiple lines of treatment. Additionally, 1 showed that avatrombopag resulted in an increase in platelet count and complete remission in patients with aplastic anemia (AA) secondary to chemoradiotherapy.

Reasons for side effects

Avatrombopag is a drug that promotes platelet production. Therefore, there is a possibility of side effects such as excessive platelet production and thrombosis. However, these side effects were mild in most patients and did not require discontinuation of treatment.

Common Side Effects

Thrombocytosis

Since avatrombopag is a drug that promotes platelet production, an increase in platelet count has been reported. 2 did not report any patients who experienced an increase in platelet count during avatrombopag administration, but 1 reported thrombocytosis. Thrombocytosis is usually mild and does not require discontinuation of treatment. 1

Nausea

Nausea was reported in 1 . Nausea is usually mild and does not require discontinuation of treatment.

Side Effects Management

Thrombocytosis

If thrombocytosis symptoms are severe, measures such as reducing the dose of avatrombopag should be considered. 1

Comparison of Studies

Commonalities of Studies

Both studies show that avatrombopag is effective in treating blood disorders caused by chemotherapy or radiation therapy. Furthermore, both studies showed that avatrombopag had good tolerability.

Differences of Studies

The two studies differ in the diseases they target. 2 focuses on chemotherapy-induced thrombocytopenia, while 1 focuses on aplastic anemia caused by radiation therapy. In addition, 2 is a single-center study, whereas 1 is a retrospective cohort study.

Points to Note Regarding Application to Real Life

Avatrombopag is a promising drug for treating blood disorders caused by chemotherapy or radiation therapy, but the possibility of side effects cannot be disregarded. Those considering taking avatrombopag should consult their doctor beforehand and understand the risks and benefits of taking the drug before deciding whether or not to take it. Additionally, it is important to undergo regular medical checkups while taking avatrombopag.

Current Research Limitations

Both of these studies are relatively small in size, so further research is needed to determine the long-term safety and efficacy of avatrombopag.

Future Research Directions

Large-scale clinical trials are needed to confirm the long-term safety and efficacy of avatrombopag. Research is also needed to determine the optimal dosage and duration of administration of avatrombopag. Additionally, research exploring the efficacy of avatrombopag in other blood disorders is eagerly awaited.

Conclusion

Avatrombopag may be an effective drug for treating blood disorders caused by chemotherapy or radiation therapy. However, the risk of side effects cannot be disregarded. Those considering taking avatrombopag should consult their doctor beforehand and understand the risks and benefits of taking the drug before deciding whether or not to take it.